EGFR and non-small cell lung carcinoma: On the other hand, some of the targeted therapies are used in conjunction with certain companion diagnostics: EGFR tyrosine kinase inhibitors (TKIs) and crizotinib have been approved in the first line of NSCLC in the case of activating mutations in the tyrosine kinase domain of EGFR and the presence of anaplastic lymphoma kinase (ALK) translocations, respectively [7].